The essential resource for your practice
Volume XXI, Number
Health Policy 101 with Drs. Mark Edney and Jim Dupree
On June 4, 2012, Northwestern University hosted a first-of-its kind health policy event for urology residents: Health Policy 101. Dr. Mark Edney, the AUA's 2012-2013 Gallagher Health Policy Scholar, delivered a presentation and facilitated a discussion with more than 20 residents from five different training programs in the greater Chicago area.
Table of Contents
2012 Alliance of Specialty Medicine Fly-In
Senate Testimony in Support of Soldiers with Genitourinary Injuries
Mark T. Edney, MD
In mid-June, I was asked by Senator Patty Murray (D-WA) to testify at the Senate Committee on Veterans Affairs hearing on behalf of her bill, S. 3313, the Women Veterans and Other Health Care Improvements Act of 2012. Among other provisions, the bill seeks to establish coverage in the Department of Veterans Affairs (VA) system for advanced reproductive treatment for soldiers who have suffered fertility-impairing injuries. I was privileged to be able to advocate on behalf of these soldiers and a unique class of urology patients. Both my written testimony and the video of the hearing are available to view.
For The Record
Medicare Physician Fee Schedule Proposed Rule Appears to Soften EHR Reporting of PQRS Measures
As it currently stands through 2013, a practice’s ability to report Physician Quality Reporting System (PQRS) measures to Medicare can be accomplished via a direct reporting function from the practice’s electronic health record (EHR) system only if the system vendor has self-nominated their software, and it has been tested and approved by the Centers for Medicare & Medicaid Services (CMS).
Important Information about BCG
It is the AUA's understanding that many urology practices around the United States have been experiencing a significant shortage of bacillus Calmette-Guerin (BCG) product for the treatment of bladder cancer. We understand that this is a critical issue affecting your bladder cancer patients, and the AUA has been in touch with the makers of BCG therapies, as well as the FDA, to gather more information about the situation and provide direction to help you.
We have learned that one maker has temporarily suspended BCG production and will not have supply available until sometime in 2013. To counter the shortage, another manufacturer, Merck, has increased production of its live product, TICE® BCG, and doubled its supply in the U.S. market in order to meet the need.